Our study indicated that ARG2 could be a potential therapeutic target for IDD and confirmed that ARG2 deficiency prevents IDD by inhibiting expression of ECM-degrading enzymes, and ameliorating senescence, apoptosis, oxidative stress, and the inflammatory response in NPCs. This evidence concerns the gene ARG2 and intervertebral disk degenerative disorder.